{"id":"NCT00002651","sponsor":"SWOG Cancer Research Network","briefTitle":"SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer","officialTitle":"Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1995-05","primaryCompletion":"2013-06","completion":"2013-06","firstPosted":"2003-01-27","resultsPosted":"2017-04-17","lastUpdate":"2017-04-17"},"enrollment":3040,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"bicalutamide","otherNames":[]},{"type":"DRUG","name":"goserelin acetate","otherNames":[]},{"type":"OTHER","name":"clinical observation","otherNames":[]}],"arms":[{"label":"Consolidation arm I","type":"ACTIVE_COMPARATOR"},{"label":"Consolidation arm II","type":"EXPERIMENTAL"}],"summary":"RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer. It is not yet known which regimen of hormone therapy is most effective for stage IV prostate cancer.\n\nPURPOSE: This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Up to 15 years","effectByArm":[{"arm":"Consolidation Arm I","deltaMin":5.8,"sd":null},{"arm":"Consolidation Arm II","deltaMin":5.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.15"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["Canada"]},"refs":{"pmids":["22921015","19380444","16921051","26720308","25087673","23550669"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":732},"commonTop":["Hot flashes","Fatigue/malaise/lethargy","Erectile impotence","Bone pain","Libido loss"]}}